Secondary Outcome(s)
|
Change in the index of insulin resistance.
[Time Frame: 6 months]
|
Determine disease activity
[Time Frame: 6 months]
|
Change in levels biomarker levels biomarkers associated with MS by ELISA/multiplex Serological studies
[Time Frame: 6 months]
|
Changes in mRNA expression by gene expression studies
[Time Frame: 6 months]
|
Change in levels biomarkers of endothelial cell activation and inflammation.
[Time Frame: 6 months]
|
Determine disease activity with CDAI index ( number of painful and swollen joints with 28 joints, the activity assessment by the patient and the physician on a scale from 0 to 10 and the PCR in mg/dl)
[Time Frame: 6 months]
|
Change in PET/CT 18F-FNa uptake in the aortic wall
[Time Frame: 6 months]
|
Change in PET/CT 18F-FDG uptake in the aortic wall
[Time Frame: 6 months]
|
Modulation of the lipid profile using blood test
[Time Frame: 6 months]
|
Routine inflammatory parameters
[Time Frame: 6 months]
|
Change in the index of insulin sensitivity.
[Time Frame: 6 months]
|
Changes in serum adipocine levels by ELISA/multiplex Serological studies
[Time Frame: 6 months]
|
Determine disease activity with DAS 28 index (Rheumatoid arthritis disease activity index) with 4 items corresponding to low (DAS28 = 2.43), medium (DAS28 = 4.05), high (DAS28 = 6.32) or very high (DAS28 = 8.40) activity.
[Time Frame: 6 months]
|